# Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

> **NCT06061146** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 136 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Arm A
- **DRUG:** Arm A
- **RADIATION:** Arm A
- **DRUG:** Arm B
- **RADIATION:** Arm B

## Key facts

- **NCT ID:** NCT06061146
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-05
- **Primary completion:** 2024-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2023-12-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06061146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06061146, "Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06061146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*